Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan

被引：0
|
作者：
Benjamin Chastek
Kathleen M. Fox
Crystal Watson
Shravanthi R. Gandra
机构：
[1] OptumInsight,
[2] Strategic Healthcare Solutions,undefined
[3] LLC,undefined
[4] Amgen Inc.,undefined
来源：
Advances in Therapy | 2012年 / 29卷
关键词：
Adalimumab; Etanercept; Discontinuation; Persistence; Psoriatic arthritis; Switch; Treatment patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 697
页数：6
相关论文
共 50 条
  • [1] Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
    Chastek, Benjamin
    Fox, Kathleen M.
    Watson, Crystal
    Gandra, Shravanthi R.
    ADVANCES IN THERAPY, 2012, 29 (08) : 691 - 697
  • [2] Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population
    Chastek, Benjamin
    Fox, Kathleen M.
    Watson, Crystal
    Kricorian, Gregory
    Gandra, Shravanthi R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (01) : 25 - 33
  • [3] SUCCESSFUL TREATMENT WITH ETANERCEPT OF A PATIENT WITH PSORIATIC ARTHRITIS AFTER ADALIMUMAB-RELATED HEPATOTOXICITY
    Massarotti, M.
    Marasini, B.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2009, 22 (02) : 547 - 549
  • [4] Etanercept in the Treatment of Psoriatic Arthritis
    Puig, L.
    Lopez-Ferrer, A.
    Laiz, A.
    ACTAS DERMO-SIFILIOGRAFICAS, 2015, 106 (04): : 252 - 259
  • [5] Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis
    Santoleri, Fiorenzo
    Romagnoli, Alessia
    Costantini, Alberto
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (01) : 93 - 97
  • [6] Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
    Bonafede, Machaon
    Johnson, Barbara H.
    Fox, Kathleen M.
    Watson, Crystal
    Gandra, Shravanthi R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (05) : 369 - 373
  • [7] Adalimumab for the treatment of psoriatic arthritis
    Poddubnyy, Denis A.
    Rudwaleit, Martin
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (06) : 671 - 681
  • [8] Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients
    Luisa Costa
    Francesco Caso
    Mariangela Atteno
    Antonio Del Puente
    Md Abud Darda
    Paolo Caso
    Augusta Ortolan
    Ugo Fiocco
    Roberta Ramonda
    Leonardo Punzi
    Raffaele Scarpa
    Clinical Rheumatology, 2014, 33 : 833 - 839
  • [9] Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients
    Costa, Luisa
    Caso, Francesco
    Atteno, Mariangela
    Del Puente, Antonio
    Darda, Md Abud
    Caso, Paolo
    Ortolan, Augusta
    Fiocco, Ugo
    Ramonda, Roberta
    Punzi, Leonardo
    Scarpa, Raffaele
    CLINICAL RHEUMATOLOGY, 2014, 33 (06) : 833 - 839
  • [10] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
    Gladman, Dafna D.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (10): : 510 - 511
12345